Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2227-2228, 2005; 10.1373/clinchem.2005.058958
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kleerekoper, M.
Right arrow Articles by Camacho, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kleerekoper, M.
Right arrow Articles by Camacho, P.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:2227-2228.)
© 2005 American Association for Clinical Chemistry, Inc.

Editorial

Monitoring Osteoporosis Therapy

Michael Kleerekoper1 and Pauline Camacho2,a

1 Wayne State University, Detroit, MI
2 Loyola University Health System, Maywood, IL

aAddress correspondence to this author at: Loyola University Health System, 2160 S. First Avenue, Bldg 54, Maywood, IL 60153. Fax 708-216-5936; e-mail pcamach@lumc.edu.

The first 20% of the full text of this article appears below.

Osteoporosis is a prevalent condition that may exist in a silent form, in which increased fracture risk can be detected by measurement of bone mineral density (BMD), or as a symptomatic condition after a fragility fracture has occurred. In October 2004, the Surgeon General of the United States published a lengthy report on osteoporosis (1), which is a must-read for healthcare professionals interested in this disease.

The chapter "Assessing the Risk of Bone Disease and Fracture" discusses many aspects of bone mass measurement, but relegates biochemical markers of bone turnover to the subsection "Looking to the Future: Potential Complements to BMD" (1). In a sense, this designation is appropriate because these markers currently have no "diagnostic" value, whereas the WHO has designated a BMD >2.5 SD below the mean for healthy adults younger than 50 years as diagnostic for osteoporosis even in the absence of a bone fracture.

Considerable evidence exists, however, that biochemical marker data alone can be used to assess fracture risk in older persons and are additive to BMD data with respect to fracture risk prediction. In reality, neither clinical tool is optimal for this purpose. Two recent studies in older populations have pointed out that among individuals who have sustained a fragility fracture, before the fracture only 40%–45% would have been diagnosed . . . [Full Text of this Article]




eLetters:

Read all eLetters

TRACP 5b and PINP are available in the U.S.
C. Kenneth Gibbs
Clinical Chemistry Online, 9 Dec 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.